ColoSense Post-Approval Study
Geneoscopy, Inc. · NCT07069556
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 12500
- US sites recruiting
- 1
- Study start
- September 5, 2025
- Record last updated
- November 21, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The post-approval study (PAS) described here will supplement existing data generated in the CRC-PREVENT clinical trial. The primary outcomes of this supplemental study will include: clinical sensitivity, clinical specificity, positive predictive value (PPV), and negative predictive value (NPV) of ColoSense.
Being studied: ColoSense
Conditions: Colorectal Cancer (Diagnosis)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Subject is male or female, ≥45 years of age (subjects aged 18-45 can be enrolled onto the clinical trial but are not eligible for primary endpoint analysis)
- Subject is able to understand the study procedures, and is able to provide consent to participate in the study and authorizes release of relevant protected health information through reviewing and consenting to a HIPAA medical release form
- Subject is able and willing to provide stool samples within the 120 days prior to a colonoscopy procedure
- Subject is able and willing to undergo a colonoscopy after providing a stool sample
Exclusion Criteria
- Subject had any precancerous findings on most recent colonoscopy. This does not include benign, and/or hyperplastic polyps of any size
- Subject has a history or diagnosis of colorectal cancer
- Subject has a history of aerodigestive tract cancer
- Subject has had a positive non-invasive screening diagnostic within the associated recommended intervals:
- Fecal occult blood test or fecal immunochemical test within the previous twelve (12) months
- FIT-DNA test within the previous 36 months
- Subject has had a colonoscopy in the previous nine (9) years.
- Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease
- Indication for colonoscopy was due to overt rectal bleeding, e.g., hematochezia or melena, within the previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal bleeding)
- Subject has a diagnosis or personal history of any of the following high-risk conditions for colorectal cancer:
- Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease
- Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP)
- Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" of "Lynch Syndrome")
- Other hereditary cancer syndromes including but are not limited to:
- Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome
- Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis
- Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis
Recruiting US locations
Decentralized Study
St Louis, MO 63146
Site contact: Erica K Barnell, MD PhD · 314-887-7777 · contact@geneoscopy.com
Study contacts (from the official record)
- Erica K Barnell, MD PhD · 314-887-7777 · contact@geneoscopy.com
Similar studies in Missouri
All healthy volunteers studies in Missouri →- RecruitingHealthy volunteersPhase 1
A Study of V132 in Healthy Older Participants (V132-001)
Merck Sharp & Dohme LLC
- Location
- Springfield, MO + 9 other US sites
- Eligibility basics
- Ages 50–75
- RecruitingHealthy volunteersPhase 1
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)
Merck Sharp & Dohme LLC
- Location
- Springfield, MO + 5 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Kansas City, MO + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Merck Sharp & Dohme LLC
- Location
- St Louis, MO + 14 other US sites
- Eligibility basics
- Ages 2 mo–1